Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

SARS-CoV-2 antibodies wane, depending on age, symptoms and ethnicity

Researchers at the University of Oxford have conducted a study of UK healthcare workers showing how antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can wane over time, depending on age, previous symptoms and ethnicity.

8 Nov 2020

Innate immunity key to limiting viral load in COVID-19 cases

As the coronavirus disease 2019 (COVID-19) pandemic continues to cause many difficulties for public health authorities, research is ongoing to understand how the virus can cause fatal effects on those infected and thereby suggest effective preventive and therapeutic measures against it.

8 Nov 2020

Universal nanoparticle platform may help in rapid development of a COVID-19 vaccine

A research group in China recently published a paper on the pre-print server bioRxiv* that reports the performance of a potentially universal nanoparticle platform that may prove useful for the rapid development of a COVID-19 vaccine, as well as other vaccines in the future.

8 Nov 2020

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX), a prophylactic therapy to help prevent pneumocystis pneumonia, are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies.

6 Nov 2020

Study: Genetically edited form of herpes simplex virus outperforms leading vaccine candidate

A genetically edited form of a herpes simplex virus -- rewired to keep it from taking refuge in the nervous system and eluding an immune response -- has outperformed a leading vaccine candidate in a new study from the University of Cincinnati, Northwestern University and the University of Nebraska-Lincoln.

6 Nov 2020

Researchers develop novel chemo-immunotherapy agent to treat pancreatic tumors

Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

6 Nov 2020

Llama antibodies could be a potent nanoweapon against COVID-19

Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.

5 Nov 2020

Children produce different antibodies in response to infection with new coronavirus

Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.

5 Nov 2020

Study reveals new mechanism underlying immune-cell activation

When antibody-producing immune cells encounter infectious pathogens for the first time, they engage a signal cascade to generate a massive activation signal within seconds.

5 Nov 2020

Study shows T cells can prevent Zika infection in mice

Where Aedes mosquitoes fly, Zika virus may not be far behind. Although the explosive 2015–2016 Zika epidemics in the Americas are behind us, Zika may re-emerge, and "in many countries, Zika may be spreading in silence," says Sujan Shresta, Ph.D., a professor at La Jolla Institute for Immunology (LJI).

5 Nov 2020

Novel approach for modeling spread of infectious disease

The rapid spread of SARS-CoV-2 across the world despite the early shutdown of borders and the cessation of international travel has sparked interest and given rise to changes in knowledge regarding the spread of infections.

4 Nov 2020

Case study reports prolonged infectious SARS-CoV-2 shedding from an asymptomatic leukemia patient

The majority of people infected with SARS-CoV-2 appear to actively shed infectious virus for about 8 days, but there is a wide range of variability from person to person.

4 Nov 2020

Researchers identify a genetic basis for ANCA-associated vasculitis

Autoimmune disease is fundamentally a mystery: whyever should an organism systematically set out to harm itself?

4 Nov 2020

Black, Latinx hospital workers at highest risk for SARS-CoV-2 infection, study finds

Support staff and Black and Latinx hospital employees with and without patient care responsibilities are at highest risk for SARS-CoV-2 infection in health care settings, a Rutgers study found.

4 Nov 2020

Synthetic antibody may prevent coronavirus from infecting human cells

By screening hundreds of synthetic antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells.

4 Nov 2020

First EUA point-of-care (POC/Waived/Fingerstick) COVID-19 antibody test now available from Carolina Liquid Chemistries.

The Fastep® COVID-19 IgG/IgM Rapid Test Device by Assure Tech., distributed in the USA by Carolina Liquid Chemistries, has received FDA Emergency Use Authorization for use.

From Carolina Liquid Chemistries Corp. 4 Nov 2020

Researchers identify genetic basis for anti-neutrophil cytoplasmic antibody-associated vasculitis

Autoimmune disease is fundamentally a mystery: whyever should an organism systematically set out to harm itself?

4 Nov 2020

Most SARS-CoV-2-infected individuals develop durable B cell-mediated immunity

Researchers from the Johns Hopkins University and The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA, investigated the durability of B cell immunity following SARS-CoV-2 infection and recovery in their recent work published on the preprint server medRxiv.

3 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020

SARS-CoV-2 T-cell immunity is retained for at least six months

Now, a new study published on the preprint server bioRxiv shows that functional SARS-CoV-2-specific T-cell responses are retained for six months following infection. However, the strength of this response depends on the clinical features of the primary infection.

3 Nov 2020